19:48:06 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-07-23 Kvartalsrapport 2024-Q2
2024-05-23 Ordinarie utdelning SEDANA 0.00 SEK
2024-05-22 Årsstämma 2024
2024-04-25 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-21 Kvartalsrapport 2023-Q2
2023-05-17 Ordinarie utdelning SEDANA 0.00 SEK
2023-05-16 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-10-25 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-05-12 Ordinarie utdelning SEDANA 0.00 SEK
2022-05-11 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-26 Split SEDANA 1:4
2021-05-11 Ordinarie utdelning SEDANA 0.00 SEK
2021-05-10 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning SEDANA 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-03-05 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning SEDANA 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-21 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-23 Ordinarie utdelning SEDANA 0.00 SEK
2018-05-22 Kvartalsrapport 2018-Q1
2018-05-22 Årsstämma 2018
2018-03-27 Bokslutskommuniké 2017
2017-11-30 Kvartalsrapport 2017-Q3

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Sedana Medical är verksamt inom medicinteknik. Bolaget arbetar idag med AnaConDa-teknologi, vilket innefattar transformeringen av flytande vätska till gas. Tekniken används vanligtvis för intensivvårdspatienter vid nedsövning och skiljer sig gentemot den traditionella behandlingen som tidigare utgetts intravenöst med läkemedel. Bolaget har sitt huvudkontor i Danderyd.
2023-01-20 13:30:00

Sedana Medical AB (publ) (the "Company" or "Sedana Medical") announced on 19 January 2023 that Nasdaq Stockholm's listing committee had approved the Company's application for admission to trading of the Company's shares on Nasdaq Stockholm. The Company has prepared a prospectus in connection with the listing change, which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the "Prospectus"). The Prospectus (only in Swedish) is available on the Company's website.

Publication of the Prospectus

For complete information about the listing change, reference is made to the Prospectus that has been prepared by the Company and made available on the Company's website (www.sedanamedical.se).

The Prospectus has been prepared as a simplified prospectus in accordance with Article 14 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "Prospectus Regulation"). The Swedish Financial Supervisory Authority (the ''SFSA''), as the Swedish national competent authority, has approved the Prospectus in accordance with Article 20 of the Prospectus Regulation. The SFSA only approves the Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of the Company or of the securities described in the Prospectus. The SFSA does not guarantee the accuracy or completeness of the factual information contained in the Prospectus. Each investor is advised to make its own assessment of whether it is appropriate to invest in the Company's shares.

The listing change is not combined with any offer of shares. The Company's shares will continue to trade under the ticker SEDANA and ISIN code SE0015988373. The Company's shareholders are not required to take any actions due to the listing change.

Timetable

First day of trading on Nasdaq Stockholm is scheduled for 25 January 2023 and last day of trading on Nasdaq First North Growth Market is scheduled for 24 January 2023.

New financial information

The prospectus contains certain financial information regarding Sedana Medical's capitalization and net indebtedness as of 31 October 2022 that has not previously been published. The new financial information is presented in the tables below. The information has not been reviewed by the Company's auditor.

Capitalization (KSEK)

Total current liabilities (31 October 2022) (including current 45,029
portion of non-current liabilities)
Guaranteed -
Secured -
Unguaranteed/unsecured 45,029
Total non-current liabilities (31 October 2022) (excluding current 3,684
portion of non-current liabilities)
Guaranteed -
Secured -
Unguaranteed/unsecured 3,684
Equity (31 October 2022) 1,052,152
Share capital 2,483
Legal reserve(s) 344,790
Other reserves 704,879

Net indebtedness (KSEK)

Net indebtedness (31 October 2022)
A. Cash 643,950
B. Cash equivalents -
C. Other current financial assets -
D. Liquidity (A+B+C) 643,950
E. Current financial liabilities (including debt instruments, but 5,059
excluding current portion of non-current financial liabilities)
F. Current portion of non-current financial liabilities -
G. Current financial indebtedness (E + F) 5,059
H. Current financial net indebtedness (G - D) -638,891
I. Non-current financial liabilities (excluding current portion and 3,684
debt instruments)
J. Debt instruments -
K. Non-current trade and other payables -
L. Non-current financial indebtedness (I + J + K) 3,684
M. Total financial indebtedness (H + L) -635,207

Advisers

Pareto Securities AB and Advokatfirman Lindahl KB are Sedana Medical's financial and legal advisers respectively, in connection with the listing change.

For additional information, please contact:
Johannes Doll, CEO, +46 76 303 66 66
Johan Spetz, CFO, +46 730 36 37 89
ir@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.